Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jul 23, 2026, 1:34 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Chimera Clear all
Completed Phase 1 Interventional

Repeat-Dose Study of Bavituximab in Patients With Chronic Hepatitis C

NCT00343525
View directory record Official record
Conditions
Hepatitis C
Interventions
bavituximab
Drug
Lead sponsor
Peregrine Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2006
U.S. locations
2
States / cities
Sarasota, Florida • San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated May 6, 2008 · Synced Jul 23, 2026, 1:34 PM EDT
Withdrawn Phase 1 Interventional

A Study of TAK-007 in Adults With Refractory Lupus Nephritis (LN) or Refractory Systemic Sclerosis (SSc)

NCT06377228
View directory record Official record
Conditions
Refractory Lupus Nephritis, Refractory Systemic Sclerosis
Interventions
TAK-007, Chemotherapy Agents
Biological · Drug
Lead sponsor
Takeda
Industry
Eligibility
18 Years to 75 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2030
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Apr 5, 2025 · Synced Jul 23, 2026, 1:34 PM EDT
Active, not recruiting Phase 1 Interventional

3rd Generation GD-2 Chimeric Antigen Receptor and iCaspase Suicide Safety Switch, Neuroblastoma, GRAIN

NCT01822652
View directory record Official record
Conditions
Neuroblastoma
Interventions
iC9-GD2 T Cells - frozen, iC9-GD2 T Cells - fresh, Cytoxan, Fludara, Keytruda, iC9-GD2 T cells
Genetic · Drug
Lead sponsor
Baylor College of Medicine
Other
Eligibility
Not listed
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2030
U.S. locations
2
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Apr 5, 2026 · Synced Jul 23, 2026, 1:34 PM EDT
Recruiting Phase 2 Interventional

A Study of NX-5948 in Adults With CLL/SLL Previously Treated With a Bruton's Tyrosine Kinase Inhibitor and a B-cell Lymphoma-2 Inhibitor (DAYBreak CLL-201)

NCT07221500
View directory record Official record
Conditions
Chronic Lymphocytic Leukemia (CLL), Small Lymphocytic Lymphoma (SLL)
Interventions
NX-5948
Drug
Lead sponsor
Nurix Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2030
U.S. locations
20
States / cities
Duarte, California • Denver, Colorado • Coral Gables, Florida + 16 more
Source: ClinicalTrials.gov public record
Updated Jul 1, 2026 · Synced Jul 23, 2026, 1:34 PM EDT
Active, not recruiting Phase 1 Interventional

iC9-GD2-CAR-VZV-CTLs/Refractory or Metastatic GD2-positive Sarcoma and Neuroblastoma

NCT01953900
View directory record Official record
Conditions
Osteosarcoma, Neuroblastoma
Interventions
GD2 T cells, VZV vaccine, Fludarabine, Cyclophosphamide
Genetic · Biological · Drug
Lead sponsor
Baylor College of Medicine
Other
Eligibility
Not listed
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2034
U.S. locations
2
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Apr 21, 2026 · Synced Jul 23, 2026, 1:34 PM EDT
Active, not recruiting Phase 1 Interventional

Trial of Anti-CD19 and Anti-CD20 Bicistronic Chimeric Antigen Receptor T Cells for Treating B-Cell Malignancies

NCT05797233
View directory record Official record
Conditions
Chronic Lymphocytic Leukemia, B-Cell Chronic Lymphocytic Leukemia, Lymphoma, B-Cell
Interventions
Anti-CD19 and anti-CD20 bicistronic CAR T- cells, Cyclophosphamide, Fludarabine
Biological · Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years to 75 Years
Enrollment
58 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2029
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 15, 2026 · Synced Jul 23, 2026, 1:34 PM EDT
Completed Phase 1 Interventional

Study of Bavituximab in Patients With Chronic Hepatitis C Virus Infection

NCT00128271
View directory record Official record
Conditions
Hepatitis C
Interventions
Bavituximab
Drug
Lead sponsor
Peregrine Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2005
U.S. locations
1
States / cities
Bradenton, Florida
Source: ClinicalTrials.gov public record
Updated May 6, 2008 · Synced Jul 23, 2026, 1:34 PM EDT
Recruiting Phase 1 Interventional

Intracerebroventricular Administration of CD19-CAR T Cells (CD19CAR-CD28-CD3zeta-EGFRt-expressing Tn/Mem T-lymphocytes) for the Treatment of Central Nervous System Lymphoma

NCT05625594
View directory record Official record
Conditions
Central Nervous System Lymphoma
Interventions
Aspiration, Biospecimen Collection, Catheterization, CD19CAR-CD28-CD3zeta-EGFRt-expressing Tn/mem T-lymphocytes, Computed Tomography, Cyclophosphamide, Fludarabine, Leukapheresis, Lumbar Puncture, Magnetic Resonance Imaging, Positron Emission Tomography
Procedure · Biological · Drug
Lead sponsor
City of Hope Medical Center
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
1
States / cities
Duarte, California
Source: ClinicalTrials.gov public record
Updated Jun 2, 2026 · Synced Jul 23, 2026, 1:34 PM EDT
Active, not recruiting Phase 1Phase 2 Interventional

Claudin18.2 CAR-T (CT041) in Patients With Gastric, Pancreatic Cancer, or Other Specified Digestive Cancers

NCT04404595
View directory record Official record
Conditions
Gastric Cancer, Pancreatic Cancer
Interventions
CT041
Biological
Lead sponsor
CARsgen Therapeutics Co., Ltd.
Industry
Eligibility
18 Years to 76 Years
Enrollment
110 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2035
U.S. locations
15
States / cities
Duarte, California • Los Angeles, California • San Diego, California + 11 more
Source: ClinicalTrials.gov public record
Updated Jan 7, 2025 · Synced Jul 23, 2026, 1:34 PM EDT
Recruiting Phase 1 Interventional

GD2 Specific CAR and Interleukin-15 Expressing Autologous NKT Cells to Treat Children With Neuroblastoma

NCT03294954
View directory record Official record
Conditions
Neuroblastoma
Interventions
GINAKIT Cells, GINAKIT cells + Etanercept
Genetic · Biological
Lead sponsor
Baylor College of Medicine
Other
Eligibility
1 Year to 21 Years
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2040
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Sep 18, 2025 · Synced Jul 23, 2026, 1:34 PM EDT
Recruiting Phase 2 Interventional

Intrathecal Cytarabine, Methotrexate, and Hydrocortisone for the Prevention of High-Grade Chimeric Antigen Receptor T-Cell-Associated Neurotoxicity Syndrome

NCT06895473
View directory record Official record
Conditions
Hematopoietic and Lymphatic System Neoplasm
Interventions
Biospecimen Collection, Cytarabine, Lumbar Puncture, Methotrexate, Therapeutic Hydrocortisone
Procedure · Drug
Lead sponsor
OHSU Knight Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Jun 25, 2026 · Synced Jul 23, 2026, 1:34 PM EDT
Active, not recruiting Phase 1Phase 2 Interventional

A Phase I/II Study to Evaluate AZD5851 in GPC3+ Advanced/Recurrent Hepatocellular Carcinoma

NCT06084884
View directory record Official record
Conditions
Hepatocellular Carcinoma
Interventions
AZD5851
Biological
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 130 Years
Enrollment
94 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
15
States / cities
Phoenix, Arizona • Duarte, California • Orange, California + 12 more
Source: ClinicalTrials.gov public record
Updated May 21, 2026 · Synced Jul 23, 2026, 1:34 PM EDT
Not listed Phase 1 Interventional

Allogeneic NK T-Cells Expressing CD19 Specific CAR in B-Cell Malignancies

NCT05487651
View directory record Official record
Conditions
NHL, Relapsed, Adult, B-cell Lymphoma, B-cell Leukemia, DLBCL - Diffuse Large B Cell Lymphoma, ALL, Adult B Cell, ALL, Childhood, CLL/SLL
Interventions
KUR-502
Genetic
Lead sponsor
Athenex, Inc.
Industry
Eligibility
3 Years to 75 Years
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
3
States / cities
San Francisco, California • Portland, Oregon • Houston, Texas
Source: ClinicalTrials.gov public record
Updated May 17, 2023 · Synced Jul 23, 2026, 1:34 PM EDT
Terminated Phase 1 Interventional

BCMA-directed CAR-T Cell Therapy in Adult Patients With Multiple Myeloma

NCT04318327
View directory record Official record
Conditions
Multiple Myeloma
Interventions
PHE885
Biological
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 100 Years
Enrollment
96 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2025
U.S. locations
4
States / cities
Chicago, Illinois • Boston, Massachusetts • Milwaukee, Wisconsin
Source: ClinicalTrials.gov public record
Updated Jul 8, 2026 · Synced Jul 23, 2026, 1:34 PM EDT
Recruiting Phase 1 Interventional

Infusion of Autologous T Cells Engineered to Target FSH Receptor in Recurrent Ovarian Cancer

NCT05316129
View directory record Official record
Conditions
Ovarian Cancer
Interventions
Follicle Stimulating Hormone Receptor T Cells
Drug
Lead sponsor
H. Lee Moffitt Cancer Center and Research Institute
Other
Eligibility
18 Years and older · Female only
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2029
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Dec 4, 2025 · Synced Jul 23, 2026, 1:34 PM EDT
Recruiting Phase 1 Interventional

Autologous CD22 CAR T Cells Following Commercial CD19 CAR T Cells in B Cell Malignancies

NCT06408194
View directory record Official record
Conditions
Leukemia, Acute Lymphoblastic Leukemia
Interventions
CD22CART infusion, Tisagenlecleucel
Drug
Lead sponsor
Stanford University
Other
Eligibility
1 Year to 25 Years
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
1
States / cities
Palo Alto, California
Source: ClinicalTrials.gov public record
Updated Jul 1, 2026 · Synced Jul 23, 2026, 1:34 PM EDT
Completed Phase 2 Interventional Results available

Dose Optimization Trial of CD19 Redirected Autologous T Cells

NCT01747486
View directory record Official record
Conditions
Adult Patients Who Have Relapsed or Refractory CLL (3rd Line) or SLL
Interventions
CART-19
Biological
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years and older
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2018
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jun 21, 2023 · Synced Jul 23, 2026, 1:34 PM EDT
Active, not recruiting Phase 1 Interventional

Glypican 3-specific Chimeric Antigen Receptor Expressed in T Cells for Patients With Pediatric Solid Tumors (GAP)

NCT02932956
View directory record Official record
Conditions
Liver Cancer
Interventions
GAP T cells, Cytoxan, Fludara
Genetic · Drug
Lead sponsor
Baylor College of Medicine
Other
Eligibility
1 Year to 21 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2037
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Sep 18, 2025 · Synced Jul 23, 2026, 1:34 PM EDT
Active, not recruiting Phase 1 Interventional

huCART-meso + VCN-01 in Pancreatic and Ovarian Cancer

NCT05057715
View directory record Official record
Conditions
Pancreatic Cancer, Serous Ovarian Cancer
Interventions
VCN-01, huCART-meso Cells
Biological
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years and older
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2038
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jul 12, 2026 · Synced Jul 23, 2026, 1:34 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Safety of and Immune Response to a West Nile Virus Vaccine (WN/DEN4delta30) in Healthy Adults

NCT00537147
View directory record Official record
Conditions
West Nile Fever
Interventions
WN/DEN4delta30 vaccine, Placebo
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 50 Years
Enrollment
26 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2009
U.S. locations
2
States / cities
Washington D.C., District of Columbia • Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jan 2, 2013 · Synced Jul 23, 2026, 1:34 PM EDT
Completed Phase 1 Interventional

A Study of JNJ-75229414 for Metastatic Castration-resistant Prostate Cancer Participants

NCT05022849
View directory record Official record
Conditions
Prostatic Neoplasms
Interventions
JNJ-75229414, Bridging Therapy
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years and older · Male only
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
8
States / cities
Duarte, California • Louisville, Kentucky • Minneapolis, Minnesota + 4 more
Source: ClinicalTrials.gov public record
Updated Apr 16, 2026 · Synced Jul 23, 2026, 1:34 PM EDT
Recruiting Phase 1Phase 2 Interventional

LYL273 for Patients With Relapsed or Refractory mCRC

NCT05319314
View directory record Official record
Conditions
Colorectal Cancer
Interventions
LYL273
Drug
Lead sponsor
Lyell Immunopharma, Inc.
Industry
Eligibility
18 Years and older
Enrollment
155 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2032
U.S. locations
4
States / cities
Duarte, California • San Francisco, California • Aurora, Colorado + 1 more
Source: ClinicalTrials.gov public record
Updated Jun 8, 2026 · Synced Jul 23, 2026, 1:34 PM EDT
Completed Phase 1 Interventional

Safety Study of Chimeric Antigen Receptor Modified T-cells Targeting NKG2D-Ligands

NCT02203825
View directory record Official record
Conditions
Acute Myeloid Leukemia, Myelodysplastic Syndrome, Multiple Myeloma
Interventions
CM-CS1 T-cell infusion
Biological
Lead sponsor
Celyad Oncology SA
Industry
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated May 31, 2018 · Synced Jul 23, 2026, 1:34 PM EDT
Not yet recruiting Phase 1 Interventional

Autologous B7-H3 Chimeric Antigen Receptor T Cells in Previously Treated Extensive-Stage Small Cell Lung Cancer With Recurrent or Refractory Disease

NCT07509034
View directory record Official record
Conditions
Extensive-Stage Small Cell Lung Cancer, Extrapulmonary Neuroendocrine Carcinoma, Recurrent or Refractory, Solid Tumors
Interventions
Autologous B7-H3 CAR T, Cyclophosphamide, Fludarabine
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years to 120 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2031
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 22, 2026 · Synced Jul 23, 2026, 1:34 PM EDT